After today's Teva presentation I'm starting to favor choice #2.
I know that you're joking about "starting over", but I think that whatever news the FDA delivers, it won't be good for Teva.
As long as the media/analysts/whomever spins this news in a reasonably truthful and accurate manner (the best we can hope for) things should be looking up for MNTA.
Best of luck.
Addendum: I just read poorgradstudent's post on the BV board, he's expecting Teva to get a "to-do list" from the FDA in January.